These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27430176)

  • 1. Neutrophil/Lymphocyte Ratio in Patients with Rheumatoid Arthritis Treated with Biological Agents.
    Koiwa M; Goto S; Takahashi K; Kamada T; Takai S; Nakamura H
    J Nippon Med Sch; 2016; 83(3):118-24. PubMed ID: 27430176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab.
    Sargin G; Senturk T; Yavasoglu I; Kose R
    Int J Rheum Dis; 2018 Dec; 21(12):2122-2127. PubMed ID: 30338636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
    Kizaki K; Yamashita F; Hayashi T; Funakoshi N
    Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of neutrophil-to-lymphocyte ratio as a measure of inflammation in rheumatoid arthritis.
    Chandrashekara S; Mukhtar Ahmad M; Renuka P; Anupama KR; Renuka K
    Int J Rheum Dis; 2017 Oct; 20(10):1457-1467. PubMed ID: 28952205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association Between Neutrophil/Lymphocyte Ratio and Disease Activity in Rheumatoid Arthritis and Ankylosing Spondylitis.
    Mercan R; Bitik B; Tufan A; Bozbulut UB; Atas N; Ozturk MA; Haznedaroglu S; Goker B
    J Clin Lab Anal; 2016 Sep; 30(5):597-601. PubMed ID: 26666737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy.
    Ghang B; Kwon O; Hong S; Lee CK; Yoo B; Kim YG
    Mod Rheumatol; 2017 May; 27(3):405-410. PubMed ID: 27686747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
    Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
    Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlooked hematological markers of disease activity in rheumatoid arthritis.
    Tekeoğlu İ; Gürol G; Harman H; Karakeçe E; Çiftçi İH
    Int J Rheum Dis; 2016 Nov; 19(11):1078-1082. PubMed ID: 26620362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis.
    Chandrashekara S; Rajendran A; Bai Jaganath A; Krishnamurthy R
    Reumatismo; 2015 Dec; 67(3):109-15. PubMed ID: 26876190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
    Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
    Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
    Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
    Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy.
    Boulos D; Proudman SM; Metcalf RG; McWilliams L; Hall C; Wicks IP
    Semin Arthritis Rheum; 2019 Dec; 49(3):373-376. PubMed ID: 31248587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.
    Hirata S; Marotta A; Gui Y; Hanami K; Tanaka Y
    Arthritis Res Ther; 2015 Oct; 17():280. PubMed ID: 26449724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.